The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Issues sJIA Recommendations, SSc Classification Criteria

ACR Issues sJIA Recommendations, SSc Classification Criteria

October 1, 2013 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Treatment Guidelines, Broader Criteria a Boon for Patients

You Might Also Like
  • New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica
  • ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome
  • New Classification Criteria for SLE: Proposed ACR/EULAR Criteria aim for high sensitivity & specificity
Explore This Issue
October 2013
Also By This Author
  • Legalities of Telemedicine

Two new documents from the ACR were released this October, representing the latest data and consensus about systemic juvenile idiopathic arthritis (sJIA) and systemic sclerosis (SSc). The first document, which details treatment options for sJIA, is the first update of the ACR’s recommendations on pediatric rheumatic disease that were released two years ago. The second document, a joint effort of the ACR and the European League Against Rheumatism (EULAR), provides classification criteria for early disease in the subset of patients with SSc.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

2013 JIA Guideline Update

The 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis, published simultaneously in Arthritis & Rheumatism and Arthritis Care & Research, represents both the advances made in understanding the pathophysiology of sJIA and the rapid increase in clinical data from randomized trials about effective treatment.1 The recommendations were developed by an international panel of experts in JIA and pediatric rheumatology, as well as input from an expert in evidence-based medicine and a parent of a child with sJIA. The group used RAND/UCLA methodology.

Beyond updating the 2011 recommendations regarding use of nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) in sJIA treatment, this new document gives updated information about starting nonbiologic and biologic DMARDs and treatment options for those patients with inadequate response to their initial therapy. Most important, it includes recommendations about using the newer interleukin (IL) 1 and IL-6 inhibitor therapies. Data about the inhibitors were not available in 2011.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Recommendations for Three Phenotypes

The 2013 update gives treatment recommendations for three sJIA phenotypes, which were developed from an evaluation of 1,226 scenarios. The phenotypes are defined as: 1) active systemic features and varying degrees of synovitis; 2) no active systemic features and varying degrees of synovitis; and 3) systemic arthritis with features concerning for macrophage activation syndrome (MAS). Additionally, the document provides recommendations about repeat annual tuberculosis (TB) screening among children with JIA who, at baseline, had a negative TB evaluation.

“For those pediatric rheumatologists with a firm knowledge of the supporting literature on the treatment of sJIA, these recommendations may or may not affect their clinical practice,” says Pam Weiss, MD, MSCE, assistant professor and attending physician in the division of rheumatology at Children’s Hospital of Philadelphia. “But for pediatric rheumatologists less familiar with the literature, for adult rheumatologists caring for kids, and for general pediatricians without access to pediatric rheumatology colleagues, these guidelines should be a valuable resource for providing recommendations for the most common sJIA phenotypes that we see,” she says. Dr. Weiss and Sarah Ringold, MD, MS, assistant professor at the University of Washington School of Medicine and attending physician at Seattle Children’s Hospital, were principal investigators and coauthors of the new recommendations.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Scleroderma, Systemic Inflammatory Syndromes Tagged With: AC&R, recommendation, sJIA, SSc, systemic juvenile idiopathic arthritis, Systemic sclerosisIssue: October 2013

You Might Also Like:
  • New Osteoarthritis Recommendations and Classification Criteria for Sjögren’s Syndrome and Polymyalgia Rheumatica
  • ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome
  • New Classification Criteria for SLE: Proposed ACR/EULAR Criteria aim for high sensitivity & specificity
  • The ACR, EULAR Partner to Refine Classification System, Develop New SLE Criteria

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)